Preview

Медицинский алфавит

Расширенный поиск
Доступ открыт Открытый доступ  Доступ закрыт Доступ платный или только для Подписчиков

Атеросклероз периферических артерий и артериальная гипертония. Особенности антигипертензивной терапии

https://doi.org/10.33667/2078-5631-2019-1-3(378)-12-16

Полный текст:

Аннотация

В обзорной статье обсуждается использование антигипертензивной терапии у пациентов с артериальной гипертензией и атеросклерозом артерий нижних конечностей с позиции современных клинических рекомендаций. Обозначены цели терапии, рациональные комбинации препаратов. Обсуждены проблемы и ограничения при назначении антигипертензивной терапии пациентам с заболеваниями периферических артерий в реальной клинической практике. Постулирован приоритет фиксированных комбинаций в лечении больных с артериальной гипертензией и периферическим атеросклерозом для повышения приверженности к назначенной терапии и улучшения прогноза. Использованы литературные источники из открытых баз данных PubMed, MEDLINE, eLibrary.

Об авторах

О. Л. Барбараш
ФГБНУ «Научно-исследовательский институт комплексных проблем сердечно-сосудистых заболеваний»; ФГБОУ ВО «Кемеровский государственный медицинский университет» Минздрава России
Россия


В. В. Кашталап
ФГБНУ «Научно-исследовательский институт комплексных проблем сердечно-сосудистых заболеваний»; ФГБОУ ВО «Кемеровский государственный медицинский университет» Минздрава России
Россия


Список литературы

1. Tsioufis С, Andrikou I, Siasos G, Filis K, Tousoulis D. Anti-hypertensive treatment in peripheral artery disease. Current Opinion in Pharmacology. 2018; 39: 35-42. doi.org/10.1016/j. coph.2018.01.009.

2. Gerhard-Herman MD, Gornik HL, BarrettC, Barshes NR, Corriere MA, Drachman DE, Fleisher LA, Fowkes FG, Hamburg NM, Kinlay S et al. 2016 AHA/ACC guideline on the management of patients with lower extremity peripheral artery disease. Circulation. 2017 Mar 21; 135 (12): e686-e725. doi: 10.1161/CIR.0000000000000470.

3. Clement D. Treatment of Hypertension in Patients With Peripheral Arterial Disease: An Update. Current Hypertension Reports, 2009; 11:271-276.

4. Anand S. S., Bosch J., Eikelboom J. W., Connolly S. J., Diaz R, Widimsky P, Aboyans V, Alings M, Kakkar AK, Keltai K, Maggioni AP, Lewis BS, Störk S, Zhu J, Lopez-Jaramillo P, O'Donnell M, Commerford PJ, Vinereanu D, Pogosova N, Ryden L, Fox KAA, Bhatt DL, Misselwitz F, Varigos JD, Vanassche T, Avezum AA, Chen E, Branch K, Leong DP, Bangdiwala SI, Hart RG, Yusuf S; COMPASS Investigators. Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial. Lancet. 2018 Jan 20; 391 (10117): 219-229. doi: 10.1016/S 0140-6736( 17)32409-1.

5. Зыков МВ, Кашталап ВВ, Быкова ИС, Герман АИ, Каретникова ВН., Барбараш ОЛ. Связь мультиморбидности с риском развития сердечнососудистых осложнений у пациентов с острым коронарным синдромом. Кардиологический вестник. 2018; 2: 59-65. doi: 10.17116/Cardiobulletin201813259.

6. De Buyzere M, Clement DL. Management of hypertension in peripheral arterial disease. Progress Cardiovasc Diseases. 2008, 50: 238-263.

7. Murabito JM, Evans JC, D'Agustino RB Sr, et al.: Temporal trends in the incidence of intermittent claudication from 1950 to 1999. Am J Epidemiol 2005, 162: 430-437.

8. Dormandy JA, Rutherford RB: Management of peripheral arterial disease (PAD). TASC Working Group. TransAtlantic Inter-Society Consensus (TASC). J Vasc Surg 2000, 31: S 1-S296.

9. Steg PG, Bhatt DL, Wilson PWF, et al.: One-year cardiovascular event rates in outpatients with atherothrombosis. JAMA 2007, 297: 1197-1206.

10. ESC/ESH Guidelines for the management of arterial hypertension. The Task Force for the management of arterial hypertension of ESC and ESH. Journal of Hypertension 2018 Oct; 36 (10): 1953-2041. doi: 10.1097/HJH.0000000000001940.

11. Fowkes FG, Rudan D, Rudan I, Aboyans V, Denenberg JO, McDermott MM, Norman PE, Sampson UK, Williams LJ, Mensah GA et al.: Comparison of global estimates of prevalence and risk factors for peripheral artery disease in 2000 and2010: a systematic review and analysis. Lancet2013, 382: 1329-1340.

12. Meijer WT, Grobbee DE, Hunink MG, Hofman A, Hoes AW: Determinants of peripheral arterial disease in the elderly: the Rotterdam study. Arch Intern Med 2000, 160: 2934-2938.

13. Clement DL. Can we use b-blocking agents in patients with peripheral artery disease? Hypertension 2011, 58: 138-139.

14. Emdin CA, Anderson SG, Callender T, Conrad N, Salimi- Khorshidi G, Mohseni H, Woodward M, Rahimi K: Usual blood pressure, peripheral arterial disease, and vascular risk: cohort study of 4.2 million adults. BMJ 2015, 351: h4865.

15. Garg PK, Biggs ML, Carnethon M, Ix JH, Criqui MH, Britton KA, Djousse' L, Sutton-Tyrrell K, Newman AB, Cushman M et al.: Metabolic syndrome and risk of incident peripheral artery disease: the cardiovascular health study. Hypertension 2014, 63: 413-419.

16. Wright JT, Williamson JD, Whelton PK, Snyder JK, Sink KM, Rocco MV, Reboussin DM, Rahman M, Oparil S, Lewis CE et al. SPRINT Research Group: A randomized trial of intensive versus standard blood-pressure control. N Engl J Med 2015, 373: 2103-2116.

17. Bavry AA, Anderson RD, Gong Y, Denardo SJ, Cooper-Dehoff RM, Handberg EM, Pepine CJ: Outcomes among hypertensive patients with concomitant peripheral and coronary artery disease: findings from the INternationalVErapamil-SR/ TrandolaprilSTudy. Hypertension 2010, 55:48-53.

18. Mancia G, Fagard R, Narkiewicz K, Redon J, Zanchetti A, Bo" hm M, Christiaens T, Cifkova R, De Backer G, Dominiczak A et al.: 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 2013, 34: 2159-2219.

19. Aboyans V, Ricco JB, Bartelink ML, Bjorck M, Brodmann M, Cohnert T, Collet JP, Czerny M, De Carlo M et al.: Endorsed by: the European Stroke Organization (ESO) The Task Force for the Diagnosis and Treatment of Peripheral Arterial Diseases of the European Society of Cardiology (ESC) and of the European Society for Vascular Surgery (ESVS): 2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS): Document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteries. Eur Heart J 2017: ehx095 dx. doi.org/10.1093/eurheartj/ehx095.

20. Whelton PK, Carey RM, Aronow WS, Casey DE Jr, Collins KJ, Dennison Himmelfarb C, DePalma SM, Gidding S, Jamerson KA et al.: 2017 ACC/AHA/ AAPA/ABC/ACPM/AGS/APhA/ASH/ ASPC/NMA/ PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/ American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol 2017. pii: S 0735-1097 (17) 41519-1.

21. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G: Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000, 342: 145-153.

22. Ostergren J, Sleight P, Dagenais G, Danisa K, Bosch J, Qilong Y, Yusuf S. HOPE study investigators: Impact of ramipril in patients with evidence of clinical or subclinical peripheral arterial disease. Eur Heart J 2004, 25: 17-24.

23. Yusuf S, Teo KK, Pogue J, Dyal L, Copland I, Schumacher H, Dagenais G, Sleight P, Anderson C: Telmisartan, ramipril, or both in patients at high risk for vascular events. ONTARGET Investigators. N Engl J Med 2008, 358: 1547-1559.

24. Armstrong EJ, Chen DC, Singh GD, Amsterdam EA, Laird JR: Angiotensin-converting enzyme inhibitor or angiotensin receptor blocker use is associated with reduced major adverse cardiovascular events among patients with critical limb ischemia. Vasc Med Lond Engl2015,20:237-244.

25. Zanchetti A, Julius S, Kjeldsen S, McInnes GT, Hua T, Weber M, Laragh JH, Plat F, Battegay E, Calvo-Vargas C et al.: Outcomes in subgroups of hypertensive patients treated with regimens based on val-sartan and amlodipine: an analysis of findings from the VALUE trial. J Hypertens 2006,24:2163-2168.

26. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group: Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002,288:2981-2997.

27. Piller LB, Simpson LM, Baraniuk S, Habib GB, Rahman M, Basile JN, Dart RA, Ellsworth AJ, Fendley H, Probstfield JL, et al.: ALLHAT Collaborative Research Group: Characteristics and long-term follow-up of participants with peripheral arterial disease during ALLHAT. J Gen Intern Med 2014, 29: 1475-1483.

28. Pitt B, Byington RP, Furberg CD et al. Effect of amlodipine on the progression of atherosclerosis and the occurrence of clinical events. PREVENT Investigatorsio Circulation. 2000; 13 (102): 1503-1510.

29. Nissen SE, Tuzcu EM, Libby P et al. Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: the CAMELOT study: a randomized controlled trial. JAMA. 2004; 18 (292): 2217-2225.

30. Lane DA, Lip GY: Treatment of hypertension in peripheral arterial disease. Cochrane Database Syst Rev 2013, 12: CD 003075.

31. Shahin Y, Mazari F, Chetter I: Do angiotensin converting enzyme inhibitors improve walking distance in patients with symptomatic lower limb arterial disease? A systematic review and meta-analysis of randomised controlled trials. Int J Surg 2011, 9:209-213.

32. Thomopoulos C, Parati G, Zanchetti A: Effects of blood-pressure-lowering treatment on outcome incidence in hypertension: 10 - Should blood pressure management differ in hypertensive patients with and without diabetes mellitus? Overview and meta-analyses of randomized trials. J Hypertens 2017, 35: 922-944.

33. Espinola-Klein C, Weisser G, Jagozinski A, Savvidis S, Warnholtz A, Ostad MA, Gori T, Munzel T: b-Blockers in patients with intermittent claudication and arterial hypertension: results from the Nebivolol or Metoprolol in Arterial Occlusive Disease Trial. Hypertension 2011, 58: 148-154.

34. Ankle Brachial Index Collaboration, Fowkes FG, Murray GD, Butcher I, Heald CL, Lee RJ, Chambless LE, Folsom AR, Hirsch AT, Dramaix M, deBacker G et al. Ankle brachial index combined with Framingham Risc Score to predict cardiovascular events and mortality: a meta-analysis. JAMA 2008, 300: 197-208.

35. Diehm C, Pittrow D, Lawall H: Effect of nebivolol vs. hydrochlorothiazide on the walking capacity in hypertensive patients with intermittent claudication. J Hypertens 2011, 29: 1448-1456.

36. Radack K, Deck C: b-Adrenergic blocker therapy does not worsen intermittent claudication in subjects with peripheral arterial disease: a metaanalysis of randomized controlled trials. Arch Intern Med 1991, 151: 1769-1776.

37. Paravastu SC, Mendonca DA, Da Silva A: Beta-blockers for peripheral arterial disease. Cochrane Database Syst Rev 2013, 9: CD 005508.

38. Miyajima R, Sano K, Yoshida H: Beta-adrenergic blocking agents and intermittent claudication: systematic review. Yakugaku Zasshi. 2004; 124:825-831.

39. Soga Y, Iida O, Takahara M, Hirano K, Suzuki K, Kawasaki D: Beta-blocker treatment does not worsen critical limb ischemia in patients receiving endovascular therapy. J Atheroscler Thromb. 2015; 22: 481-489.

40. MiraultT, Galloula A, Cambou JP, Lacroix P, Aboyans V, Boulon C, Constans J, Bura-Riviere A, Messas E: Impact of beta blockers on general and local outcome in patients hospitalized for lower extremity peripheral artery disease: The COPART Registry. Medicine (Baltimore) 2017, 96: e5916.

41. Aronow WS, Ahn C: Effect of beta blockers on incidence of new coronary events in older persons with prior myocardial infarction and symptomatic peripheral arterial disease. Am J Cardiol 2001, 87: 1284-1286.

42. Муромцева Г. А., Концевая А. В., Константинов В. В., Артамонова Г. В. и др. Распространенность факторов риска неинфекционных заболеваний в Российской популяции в 2012-2013 гг. Результаты исследования ЭССЕ-РФ. Кардиоваскулярная терапия и профилактика.- 2014.- № 13 (6).- С. 4-11. doi. org/10.15829/1728-8800-2014-6.

43. Jones PH, Davidson MH, Stein EA et al. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR Trial). Am. J. Cardiol. 2003; 92 (2): 152-160.

44. Crouse JR, Raichlen JS, Riley WA et al. Effect of rosuvastatin on progression of carotid intimamedia thickness in low-risk individuals with subclinical atherosclerosis: the METEOR Trial. JAMA. 2007; 297 (12): 1344-1353.

45. Ridker PM, Danielson E, Fonseca FA et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N. Engl. J. Med. 2008; 359 (21): 2195-2207.

46. Диагностика и коррекция нарушений нарушений липидного обмена с целью профилактики и лечения атеросклероза. Российские рекомендации IV пересмотр. Атеросклероз и дислипидемии. 2017; 3 (28): 5-22.

47. Остроумова О. Д., Первичко Е. И. Влияние фиксированной комбинации Экватор на уровень артериального давления и когнитивные функции у пожилых больных с артериальной гипертонией. Системные гипертензии. 2013; I (10): 76-79.


Для цитирования:


Барбараш О.Л., Кашталап В.В. Атеросклероз периферических артерий и артериальная гипертония. Особенности антигипертензивной терапии. Медицинский алфавит. 2019;1(3):12-16. https://doi.org/10.33667/2078-5631-2019-1-3(378)-12-16

For citation:


Barbarash O.L., Kashtalap V.V. Atherosclerosis of peripheral arteries and arterial hypertension. Features of antihypertensive therapy. Medical alphabet. 2019;1(3):12-16. (In Russ.) https://doi.org/10.33667/2078-5631-2019-1-3(378)-12-16

Просмотров: 100


ISSN 2078-5631 (Print)